FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280490350> ?p ?o ?g. }

• W4280490350 abstract "Abstract Background Plasmodium vivax forms dormant liver stages that can reactivate weeks or months following an acute infection. Recurrent infections are often associated with a febrile illness and can cause a cumulative risk of severe anaemia, direct and indirect mortality, and onward transmission of the parasite. There is an increased risk of P. vivax parasitaemia following falciparum malaria suggesting a rationale for universal use of radically curative treatment in patients with P. falciparum malaria even in the absence of detectable P. vivax parasitaemia in areas that are co-endemic for both species. Methods This is a multicentre, health care facility-based, randomized, controlled, open-label trial in Bangladesh, Indonesia and Ethiopia. Patients with uncomplicated falciparum malaria, G6PD activity of ≥70% of the adjusted male median (AMM) and haemoglobin levels ≥8g/dl are recruited into the study and randomized to either receive standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg) or standard care in a 1:1 ratio. Patients are followed up weekly until day 63. The primary endpoint is the incidence risk of any P. vivax parasitemia on day 63. Secondary endpoints include incidence risk on day 63 of symptomatic P. vivax malaria and the risk of any P. falciparum parasitaemia. Secondary safety outcomes include the proportion of adverse events and serious adverse events, the incidence risk of severe anaemia (Hb<5g/dl and <7g/dl) and/or the risk for blood transfusion, the incidence risk of ≥ 25% fall in haemoglobin with and without haemoglobinuria, and the incidence risk of ≥ 25% fall in haemoglobin to under 7g/dl with and without haemoglobinuria. Discussion This study evaluates the potential benefit of a universal radical cure for both P. vivax and P. falciparum in different endemic locations. If found safe and effective universal radical cure could represent a cost-effective approach to clear otherwise unrecognised P. vivax infections and hence accelerate P. vivax elimination. Trial registration NCT03916003 . Registered on 12 April 2019." @default.
• W4280490350 created "2022-05-22" @default.
• W4280490350 creator A5006896277 @default.
• W4280490350 creator A5013341724 @default.
• W4280490350 creator A5015962274 @default.
• W4280490350 creator A5019034894 @default.
• W4280490350 creator A5027215070 @default.
• W4280490350 creator A5027888434 @default.
• W4280490350 creator A5039761826 @default.
• W4280490350 creator A5044425282 @default.
• W4280490350 creator A5044666565 @default.
• W4280490350 creator A5045743508 @default.
• W4280490350 creator A5048088594 @default.
• W4280490350 creator A5048718850 @default.
• W4280490350 creator A5050939729 @default.
• W4280490350 creator A5052537138 @default.
• W4280490350 creator A5054296209 @default.
• W4280490350 creator A5061309607 @default.
• W4280490350 creator A5061311898 @default.
• W4280490350 creator A5070397987 @default.
• W4280490350 creator A5071140149 @default.
• W4280490350 creator A5080301344 @default.
• W4280490350 creator A5086476653 @default.
• W4280490350 creator A5091704160 @default.
• W4280490350 creator A5091743305 @default.
• W4280490350 date "2022-05-18" @default.
• W4280490350 modified "2023-10-14" @default.
• W4280490350 title "Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)" @default.
• W4280490350 cites W2100876932 @default.
• W4280490350 cites W2154179758 @default.
• W4280490350 cites W2615580270 @default.
• W4280490350 cites W2753799402 @default.
• W4280490350 cites W2764336450 @default.
• W4280490350 cites W2884033046 @default.
• W4280490350 cites W2905555152 @default.
• W4280490350 cites W2962409343 @default.
• W4280490350 cites W3106462464 @default.
• W4280490350 doi "https://doi.org/10.1186/s13063-022-06364-z" @default.
• W4280490350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35585641" @default.
• W4280490350 hasPublicationYear "2022" @default.
• W4280490350 type Work @default.
• W4280490350 citedByCount "2" @default.
• W4280490350 countsByYear W42804903502023 @default.
• W4280490350 crossrefType "journal-article" @default.
• W4280490350 hasAuthorship W4280490350A5006896277 @default.
• W4280490350 hasAuthorship W4280490350A5013341724 @default.
• W4280490350 hasAuthorship W4280490350A5015962274 @default.
• W4280490350 hasAuthorship W4280490350A5019034894 @default.
• W4280490350 hasAuthorship W4280490350A5027215070 @default.
• W4280490350 hasAuthorship W4280490350A5027888434 @default.
• W4280490350 hasAuthorship W4280490350A5039761826 @default.
• W4280490350 hasAuthorship W4280490350A5044425282 @default.
• W4280490350 hasAuthorship W4280490350A5044666565 @default.
• W4280490350 hasAuthorship W4280490350A5045743508 @default.
• W4280490350 hasAuthorship W4280490350A5048088594 @default.
• W4280490350 hasAuthorship W4280490350A5048718850 @default.
• W4280490350 hasAuthorship W4280490350A5050939729 @default.
• W4280490350 hasAuthorship W4280490350A5052537138 @default.
• W4280490350 hasAuthorship W4280490350A5054296209 @default.
• W4280490350 hasAuthorship W4280490350A5061309607 @default.
• W4280490350 hasAuthorship W4280490350A5061311898 @default.
• W4280490350 hasAuthorship W4280490350A5070397987 @default.
• W4280490350 hasAuthorship W4280490350A5071140149 @default.
• W4280490350 hasAuthorship W4280490350A5080301344 @default.
• W4280490350 hasAuthorship W4280490350A5086476653 @default.
• W4280490350 hasAuthorship W4280490350A5091704160 @default.
• W4280490350 hasAuthorship W4280490350A5091743305 @default.
• W4280490350 hasBestOaLocation W42804903501 @default.
• W4280490350 hasConcept C120665830 @default.
• W4280490350 hasConcept C121332964 @default.
• W4280490350 hasConcept C126322002 @default.
• W4280490350 hasConcept C168563851 @default.
• W4280490350 hasConcept C187212893 @default.
• W4280490350 hasConcept C197934379 @default.
• W4280490350 hasConcept C203014093 @default.
• W4280490350 hasConcept C203092338 @default.
• W4280490350 hasConcept C2775867548 @default.
• W4280490350 hasConcept C2776793103 @default.
• W4280490350 hasConcept C2777425658 @default.
• W4280490350 hasConcept C2778048844 @default.
• W4280490350 hasConcept C2778371730 @default.
• W4280490350 hasConcept C2779997623 @default.
• W4280490350 hasConcept C2911091166 @default.
• W4280490350 hasConcept C61511704 @default.
• W4280490350 hasConcept C71924100 @default.
• W4280490350 hasConcept C88879693 @default.
• W4280490350 hasConceptScore W4280490350C120665830 @default.
• W4280490350 hasConceptScore W4280490350C121332964 @default.
• W4280490350 hasConceptScore W4280490350C126322002 @default.
• W4280490350 hasConceptScore W4280490350C168563851 @default.
• W4280490350 hasConceptScore W4280490350C187212893 @default.
• W4280490350 hasConceptScore W4280490350C197934379 @default.
• W4280490350 hasConceptScore W4280490350C203014093 @default.
• W4280490350 hasConceptScore W4280490350C203092338 @default.
• W4280490350 hasConceptScore W4280490350C2775867548 @default.
• W4280490350 hasConceptScore W4280490350C2776793103 @default.
• W4280490350 hasConceptScore W4280490350C2777425658 @default.
• W4280490350 hasConceptScore W4280490350C2778048844 @default.
• W4280490350 hasConceptScore W4280490350C2778371730 @default.
• W4280490350 hasConceptScore W4280490350C2779997623 @default.

• next